BIAL
Claudio Vigini is a seasoned marketing professional with extensive experience in the pharmaceutical industry. Currently serving as the National Marketing Manager at BIAL since February 2017, Claudio previously held the position of Marketing Manager at Sandoz from 2006 to January 2017, where focus included biosimilars such as OMNITROPE and BINOCRIT. Claudio's career also features roles as Group Product Manager at HEXAL, Senior Product Manager at Lundbeck, and various Product Manager positions at CRINOS S.p.A. and Ravizza Farmaceutici - gruppo BASF Pharma. Claudio holds a degree from Università degli Studi di Milano, completed between 1989 and 1996.
This person is not in any offices
BIAL
Founded in 1924, BIAL’s mission is to discover, develop and provide new therapeutic solutions within the area of Health. Today, BIAL is an innovative international pharmaceutical company with products available in more than 50 countries. The company is committed to making a contribution to improve human health and quality of life for people from all over the world. Its strategic areas are Innovation, Internationalisation and Quality. Strongly committed to therapeutic innovation, and consistently investing more than 20% of its annual revenue in Research and Development (R&D), BIAL has established an ambitious R&D programme. The key focus area for the Group is neurosciences. The company headquarters are located in Portugal. BIAL has also facilities in Spain, Germany, United Kingdom, Italy, Switzerland, US, Mozambique, Angola, Panama and Ivory Coast. BIAL Group is a member of the “European Federation of Pharmaceutical Industries and Associations” (EFPIA). BIAL has also been distinguished by its support to several medical and scientific activities, namely through BIAL Foundation, having as outstanding events the BIAL Award in Biomedicine, the Prémio BIAL de Medicina Clínica and Scientific Research Grants, well recognized worldwide. For more information, please visit: www.bial.com For issues of safety or others related to product quality, please contact: pharmacovigilance@bial.com